



# SCHOLAR ROCK

## Scholar Rock to Participate in Upcoming Investor Conferences

March 6, 2019

CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- [Scholar Rock Holding Corporation](#) (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences:

- **Cowen and Company 39<sup>th</sup> Annual Healthcare Conference** in Boston, MA on Wednesday, March 13, 2019 with a presentation at 9:20 a.m. ET.
- **Oppenheimer's 29<sup>th</sup> Annual Healthcare Conference** in New York, NY on Tuesday, March 19, 2019 with a presentation at 3:55 p.m. ET.

A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at <http://investors.scholarrock.com>. An archived replay of the webcast will be available on the Company's website for approximately 90 days following the presentation.

### About Scholar Rock

[Scholar Rock](#) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock's newly elucidated understanding of the molecular mechanisms of growth factor activation enabled it to develop a [proprietary platform](#) for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit [www.ScholarRock.com](http://www.ScholarRock.com) or follow Scholar Rock on Twitter ([@ScholarRock](#)) and LinkedIn (<https://www.linkedin.com/company/scholar-rock/>).

*Scholar Rock® is a registered trademark of Scholar Rock, Inc.*

Scholar Rock Contact:

Investors/Media

Catherine Huchu [huchu@scholarrock.com](mailto:huchu@scholarrock.com)

917-601-1649

Media Contact:

The Yates Network

Kathryn Morris [kathryn@theyatesnetwork.com](mailto:kathryn@theyatesnetwork.com)

914-204-6412



SCHOLAR ROCK

Source: Scholar Rock